Follow-up Data Show ZYTIGA® Plus Prednisone Continues to Delay Progression of Metastatic Castration-Resistant Prostate Cancer in Patients without Prior Chemotherapy(Feb 12, 2013)

Orlando, Fla., February 12, 2013 – Janssen Research & Development, LLC [Janssen] announced today that updated results showing ZYTIGA® (abiraterone acetate) plus prednisone continued to provide statistically significant improvements in disease progression compared to placebo plus prednisone, and longer overall survival in men with metastatic castration-resistant prostate cancer.....
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news